{
    "clinical_study": {
        "@rank": "102645", 
        "arm_group": {
            "arm_group_label": "colistin pharmacokinetics", 
            "arm_group_type": "Other", 
            "description": "Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required"
        }, 
        "brief_summary": {
            "textblock": "The blood concentration of the antibiotic colistin is determined in patients in whom kidney\n      function is reduced such that a renal replacement therapy is needed.\n\n      Hypothesis:no dose reduction is needed in patients undergoing continuous renal replacement\n      therapy over 24h because colistin is sufficiently removed by this procedure."
        }, 
        "brief_title": "Colistin Pharmacokinetics in Continuous Renal Replacement Therapy", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infection", 
        "detailed_description": {
            "textblock": "After administration of intravenous Colistin multiple blood samples are drawn over one\n      dosing interval on day 1, 3, and 5 of treatment.\n\n      Patients are monitored for signs of neuro- and nephrotoxicity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male or female aged 18 years or older\n\n          -  hospitalised on the ICU\n\n          -  gram-negative infection requiring antibiotic therapy with intravenous colistin as\n             part of their routine medical care\n\n          -  clinical necessity for continuous venovenous renal replacement therapy\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity to colistin or to other polymyxins\n\n          -  Personal or family history of Myasthenia Gravis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081560", 
            "org_study_id": "COLPKZH11", 
            "secondary_id": "213DR11032"
        }, 
        "intervention": {
            "arm_group_label": "colistin pharmacokinetics", 
            "description": "Colistin i.v. three times daily as long a necessary for infection treatment", 
            "intervention_name": "Colistin", 
            "intervention_type": "Drug", 
            "other_name": "Colistin"
        }, 
        "intervention_browse": {
            "mesh_term": "Colistin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pharmacokinetics", 
            "antibiotic", 
            "Gram negative", 
            "continuous renal replacement therapy"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": {
            "contact": {
                "email": "natascia.corti@usz.ch", 
                "last_name": "Natascia Corti, MD", 
                "phone": "041 (0) 44 255 20 78"
            }, 
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital of Zurich, Dept. of Pharmacology and Toxicology"
            }, 
            "investigator": {
                "last_name": "Natascia Corti, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Colistimethate and Colistin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy (CRRT)", 
        "overall_contact": {
            "email": "natascia.corti@usz.ch", 
            "last_name": "Natascia Corti, MD", 
            "phone": "044 255 20 78"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Dept. of Pharmacology and Toxicology", 
            "last_name": "Natascia Corti, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the curve (AUC)", 
            "safety_issue": "Yes", 
            "time_frame": "predose, and 0.5, 1, 2, 4, 6, 8 hours after administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081560"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical investigation daily by assessing clinical signs and questioning the patient regarding sign of neuropathy and difficulty breathing in non intubated patients. Questioning the treating physician in intubated patients regarding objective signs of increased ventilation support.", 
                "measure": "Sings of neurotoxicity and nephrotoxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Expected average of follow up is about 14 days."
            }, 
            {
                "description": "Clinical investigation daily by assessing clinical signs and questioning the patient regarding sign of neuropathy and difficulty breathing in non intubated patients. Questioning the treating physician in intubated patients regarding objective signs of increased ventilation support. The patients will be followed for the duration of colistin administration at the dose studied.", 
                "measure": "Sings of neurotoxicity and nephrotoxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Expected average of follow up is about 14 days."
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}